Evidence map›Paper›PMID 37745518›Full record

ArticlebioRxiv : the preprint server for biology2023

Conformation Selection by ATP-competitive Inhibitors and Allosteric Communication in ERK2.

Jake W Anderson, David Vaisar, David N Jones, Laurel M Pegram, Guy P Vigers, Huifen Chen, John G Moffat, Natalie G Ahn

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jake W AndersonDepartment of Biochemistry, University of Colorado, Boulder, CO.ORCID 0000-0001-8757-7408
David VaisarDepartment of Biochemistry, University of Colorado, Boulder, CO.
David N JonesDepartment of Pharmacology, University of Colorado Anschutz Medical Center, Aurora, CO.
Laurel M PegramDepartment of Biochemistry, University of Colorado, Boulder, CO.ORCID 0000-0003-3131-9199
Guy P VigersArray BioPharma, Inc., Boulder, CO.ORCID 0000-0003-4451-8453
Huifen ChenGenentech, Inc. South San Francisco, CA, USA.
John G MoffatGenentech, Inc. South San Francisco, CA, USA.
Natalie G AhnDepartment of Biochemistry, University of Colorado, Boulder, CO.ORCID 0000-0002-2690-2630
University of Colorado Boulder · USAccenture (Switzerland) · CHUniversity of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Molecular and Cellular Dynamics in Mammalian Signal TransductionR35GM136392 · NIGMS · UNIVERSITY OF COLORADO · PI NATALIE G. AHN · 2020 to 2026
$4.2M
Predoctoral Training Program in Signaling and Cellular Regulation INCLUDE Down Syndrome SupplementT32GM142607 · NIGMS · UNIVERSITY OF COLORADO · PI Sabrina Leigh Spencer, Tin Tin Su · 2021 to 2026
$3.6M
Linking Dynamics to Catalysis and Inhibition in ERK2R01GM114594 · NIGMS · UNIVERSITY OF COLORADO · PI AHN, NATALIE G. · 2016 to 2019
$1.3M
Q Exactive HF Nanoflow LC Mass Spectrometry SystemS10OD025267 · OD · UNIVERSITY OF COLORADO · PI AHN, NATALIE G. · 2018 to 2018
$600k
600 MHz NMR console and cold probeS10OD025020 · OD · UNIVERSITY OF COLORADO DENVER · PI JONES, DAVID NIGEL · 2018 to 2018
$501k
ABI Elite ESI-QqTOF Mass Spectrometry SystemS10RR026641 · NCRR · UNIVERSITY OF COLORADO · PI AHN, NATALIE G. · 2010 to 2010
$458k
Acquisition of multi-mode, high-resolution, high-sensitivity imaging platformS10OD034218 · OD · UNIVERSITY OF COLORADO · PI ERBSE, ANNETTE H · 2023 to 2023
$153k
NCI NIH HHS P30 CA046934NCRR NIH HHS S10 RR026641NIGMS NIH HHS R01 GM114594NIGMS NIH HHS R35 GM136392NIGMS NIH HHS T32 GM142607NIH HHS S10 OD025020NIH HHS S10 OD025267NIH HHS S10 OD034218
6 · The paper itself

Abstract

Activation of the extracellular signal regulated kinase-2 (ERK2) by phosphorylation has been shown to involve changes in protein dynamics, as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) and NMR relaxation dispersion measurements. These can be described by a global exchange between two conformational states of the active kinase, named "L" and "R", where R is associated with a catalytically productive ATP-binding mode. An ATP-competitive ERK1/2 inhibitor, Vertex-11e, has properties of conformation selection for the R-state, revealing movements of the activation loop that are allosterically coupled to the kinase active site. However, the features of inhibitors important for R-state selection are unknown. Here we survey a panel of ATP-competitive ERK inhibitors using HDX-MS and NMR and identify 14 new molecules with properties of R-state selection. They reveal effects propagated to distal regions in the P+1 and helix αF segments surrounding the activation loop, as well as helix αL16. Crystal structures of inhibitor complexes with ERK2 reveal systematic shifts in the Gly loop and helix αC, mediated by a Tyr-Tyr ring stacking interaction and the conserved Lys-Glu salt bridge. The findings suggest a model for the R-state involving small movements in the N-lobe that promote compactness within the kinase active site and alter mobility surrounding the activation loop. Such properties of conformation selection might be exploited to modulate the protein docking interface used by ERK substrates and effectors.

Indexed as

cancer therapeuticsconformation selectionERK2hydrogen-deuterium exchangeinhibitorMAP kinaseNMR

Identifiers

PMID37745518
PMCPMC10515847
OpenAlexW4386724588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.